WO2024263130 - A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
National phase entry:
Publication Number
WO/2024/263130
Publication Date
26.12.2024
International Application No.
PCT/TR2024/050639
International Filing Date
10.06.2024
Title **
[English]
A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR
[French]
FORMULATION PHARMACEUTIQUE COMPRENANT DE LA LINAGLIPTINE, DE LA METFORMINE ET UN INHIBITEUR DE SGLT-2
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
MUTLU, Onur
ARI, Busra
SUNEL, Fatih
ATAK, Fadime Bilgehan
ATAMAN, Seval
YAZICI, Ozlem
SARP, Onder
Priority Data
2023/007200
19.06.2023
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2119 | |
| EPO | Filing, Examination, Granting | 8939 | |
| Japan | Filing, Examination, Granting | 2255 | |
| South Korea | Filing, Examination, Granting | 2230 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,283
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical formulation comprising linagliptin or salts thereof, metformin or salts thereof and a SGLT-2 inhibitor.[French]
La présente invention concerne une formulation pharmaceutique comprenant de la linagliptine ou des sels de celle-ci, de la metformine ou des sels de celle-ci et un inhibiteur de SGLT-2.